JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Elevated plasma pentraxin 3: a potential cardiovascular risk factor?

Medical Hypotheses 2011 December
Cardiovascular disease (CVD) is still a primary cause of death in most countries. The pathogenesis of CVD can be influenced by multiple risk factors. Recent studies suggested that the innate immune system may be involved in the development of CVD. Pentraxins are critical components of the innate immune system. Recent researches have demonstrated that elevated plasma pentraxin 3 (PTX3) is associated with cardiovascular events and cardiovascular risk factors. Thus, we hypothesized that elevated plasma PTX3 is a potential cardiovascular risk factor evidenced by the following aspects: (1) PTX3 inhibited angiogenesis and promoted restenosis, (2) the expression of PTX3 increased in advanced atherosclerotic lesions and the blood of patients with ischemic heart disorders, (3) elevated plasma PTX3 levels were associated with adverse cardiovascular outcomes. If the hypothesis is confirmed, PTX3 will be an effective target point to the prevention and treatment of CVD.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app